PreVenTB Trial Overview
The PreVenTB trial is a major study testing the effectiveness and safety of two TB vaccines, VPM1002 and Immuvac (Mw), to prevent tuberculosis (TB) in healthy individuals living with newly diagnosed TB patients. This is a Phase III, randomized, double-blind, placebo-controlled trial taking place in India.
Why This Study Matters
TB is a serious infectious disease that poses a significant risk worldwide. New preventive strategies, including effective vaccines, are urgently needed to combat this health crisis.
Study Details
The trial will involve 12,000 healthy household contacts (HHCs) aged 6 to 99 years. Participants will receive one of the following:
- VPM1002 vaccine
- Immuvac (Mw) vaccine
- Placebo
Key Objectives
- Primary goal: Prevent microbiologically confirmed TB.
- Secondary goals include:
- Preventing latent TB infection.
- Monitoring adverse events in participants.
- Assessing how effective the vaccines are across different age groups.
- Evaluating immune responses to the vaccines at specified intervals post-vaccination.
Ethics and Accountability
The study has received ethical approvals from various respected institutions. Results will be shared transparently through publications, conferences, and communications with health authorities.
Trial Registration
This trial is registered under the number: CTRI/2019/01/017026.
The Importance of Clinical Trials
Clinical trials are essential for creating safe and effective medical treatments. They help translate research findings into daily medical practices.
Practical Solutions Provided by DocSym
DocSym is an AI-driven platform designed to enhance clinical operations by consolidating important standards and protocols. Here’s how it can help:
- Streamlining scheduling and monitoring of treatments.
- Facilitating telemedicine to improve patient access.
- Reducing paper-based routines to enhance workflow efficiency.
Enhancing Patient Care
By using AI, clinics can improve patient outcomes and simplify care management. Learn more about our solutions at aidevmd.com.